These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8888118)

  • 21. Niacin-respondent subset of schizophrenia – a therapeutic review.
    Xu XJ; Jiang GS
    Eur Rev Med Pharmacol Sci; 2015; 19(6):988-97. PubMed ID: 25855923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia.
    Hudson CJ; Young LT; Li PP; Warsh JJ
    Synapse; 1993 Mar; 13(3):278-93. PubMed ID: 8497811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A volumetric biochemical niacin flush-based index that noninvasively detects fatty acid deficiency in schizophrenia.
    Puri BK; Hirsch SR; Easton T; Richardson AJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jan; 26(1):49-52. PubMed ID: 11853118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Niacin skin-flush response and electrodermal activity in patients with schizophrenia and healthy controls.
    Nilsson BM; Hultman CM; Wiesel FA
    Prostaglandins Leukot Essent Fatty Acids; 2006 May; 74(5):339-46. PubMed ID: 16600583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene targets related to phospholipid and fatty acid metabolism in schizophrenia and other psychiatric disorders: an update.
    Bennett CN; Horrobin DF
    Prostaglandins Leukot Essent Fatty Acids; 2000; 63(1-2):47-59. PubMed ID: 10970713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia.
    Fenton WS; Hibbeln J; Knable M
    Biol Psychiatry; 2000 Jan; 47(1):8-21. PubMed ID: 10650444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Normal phospholipid-related signal transduction in autism.
    Puri BK; Singh I
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Dec; 26(7-8):1405-7. PubMed ID: 12502030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Membrane phospholipid metabolism and schizophrenia: an in vivo 31P-MR spectroscopy study.
    Stanley JA; Williamson PC; Drost DJ; Carr TJ; Rylett RJ; Morrison-Stewart S; Thompson RT
    Schizophr Res; 1994 Oct; 13(3):209-15. PubMed ID: 7841133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between left frontal phospholipids and Wisconsin Card Sort Test performance in schizophrenia.
    Deicken RF; Merrin EL; Floyd TC; Weiner MW
    Schizophr Res; 1995 Jan; 14(2):177-81. PubMed ID: 7710998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of the Niacin-Blunted Subgroup of Schizophrenia Patients from Mood Disorders and Healthy Individuals in Chinese Population.
    Sun L; Yang X; Jiang J; Hu X; Qing Y; Wang D; Yang T; Yang C; Zhang J; Yang P; Wang P; Cai C; Wang J; He L; Wan C
    Schizophr Bull; 2018 Jun; 44(4):896-907. PubMed ID: 29077970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Membrane phospholipids and cytokine interaction in schizophrenia.
    Yao JK; van Kammen DP
    Int Rev Neurobiol; 2004; 59():297-326. PubMed ID: 15006493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cannabinoids influence lipid-arachidonic acid pathways in schizophrenia.
    Smesny S; Rosburg T; Baur K; Rudolph N; Sauer H
    Neuropsychopharmacology; 2007 Oct; 32(10):2067-73. PubMed ID: 17314920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Niacin skin flushing in schizophrenic and depressed patients and healthy controls.
    Bosveld-van Haandel L; Knegtering R; Kluiter H; van den Bosch RJ
    Psychiatry Res; 2006 Aug; 143(2-3):303-6. PubMed ID: 16837062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced vasodilatory response to methylnicotinate in schizophrenia as assessed by laser Doppler flowmetry.
    Ross BM; Hughes B; Turenne S; Seeman M; Warsh JJ
    Eur Neuropsychopharmacol; 2004 May; 14(3):191-7. PubMed ID: 15056478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Diseases of phospholipid metabolism as possible pathogenetic factors in schizophrenia. Current findings and critical evaluation].
    Smesny S; Volz HP; Riehemann S; Sauer H
    Fortschr Neurol Psychiatr; 2000 Jul; 68(7):301-12. PubMed ID: 10945156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia.
    Horrobin DF
    Schizophr Res; 1998 Apr; 30(3):193-208. PubMed ID: 9589514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia.
    Corfas G; Roy K; Buxbaum JD
    Nat Neurosci; 2004 Jun; 7(6):575-80. PubMed ID: 15162166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of antipsychotic treatment on membrane phospholipid metabolism in schizophrenia.
    Schmitt A; Maras A; Petroianu G; Braus DF; Scheuer L; Gattaz WF
    J Neural Transm (Vienna); 2001; 108(8-9):1081-91. PubMed ID: 11716143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 31P nuclear magnetic resonance spectroscopy: neurodevelopment and schizophrenia.
    Pettegrew JW; Keshavan MS; Minshew NJ
    Schizophr Bull; 1993; 19(1):35-53. PubMed ID: 8451612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Absent response to niacin skin patch is specific to schizophrenia and independent of smoking.
    Liu CM; Chang SS; Liao SC; Hwang TJ; Shieh MH; Liu SK; Chen WJ; Hwu HG
    Psychiatry Res; 2007 Aug; 152(2-3):181-7. PubMed ID: 17459487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.